EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

Theodore E Warkentin iD

International Journal of Laboratory Hematology · 2026-04 · 48 (2) · 259-271

DOI: 10.1111/ijlh.14486 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Laboratory Hematology, online erschienen am 13.05.2025. Verfasst von Theodore E Warkentin. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine, McMaster University, Ontario, Canada. Hauptthemen laut MEDLINE: Platelet Factor 4, Thrombocytopenia, Thrombosis, Autoantibodies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation. The identification in 2021 of an ultrarare HITT‐mimicking disorder, vaccine‐induced immune thrombocytopenia and thrombosis (VITT)—triggered by two different adenoviral vector vaccines—abruptly broadened the spectrum of recognized anti‐PF4 disorders.

Objective

To classify platelet‐activating anti‐PF4 disorders, both HITT/HITT‐like and VITT/VITT‐like.

Methods

Literature was reviewed from the perspective of a researcher‐clinician involved in identifying novel anti‐PF4 disorders.

Results

Atypical presentations of HITT with proximate heparin triggers but which evince heparin‐independent platelet‐activating properties (“autoimmune HITT”) have been recognized since 2001; heparin‐independent platelet‐activating properties also characterize HITT‐mimicking disorders with undefined non‐heparin triggers (e.g., post‐knee replacement “spontaneous HITT”). Antibodies identical to those of (vaccine‐induced) VITT can rarely be triggered by natural adenovirus infection. HITT and VITT antibodies recognize different epitopes on PF4. All the aforementioned anti‐PF4 disorders are acute, transient, and self‐limited. Recently, however, chronic anti‐PF4 disorders featuring potent VITT‐like properties of monoclonal proteins (M‐proteins) have been identified: this oftentimes treatment‐refractory entity, named “VITT‐like monoclonal gammopathy of thrombotic significance” (VITT‐like MGTS), dramatically expands the clinical spectrum of recognized anti‐PF4 disorders. Anti‐PF4 disorders with heparin‐independent platelet‐activating antibodies, whether HITT or VITT, may require management strategies beyond anticoagulation alone, including high‐dose intravenous immunoglobulin (IVIG) or (for VITT‐like MGTS) the Bruton's tyrosine kinase inhibitor, ibrutinib.

Conclusion

Clinicians and laboratorians require knowledge of the rapidly broadening spectrum of recognized acute and chronic anti‐PF4 disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Factor 4ThrombocytopeniaThrombosisAutoantibodiesPlatelet ActivationBlood PlateletsHumansHeparinImmunoglobulin G

Stichwörter der Autor:innen

VITT‐like monoclonal gammopathy of thrombotic significance (VITT‐like MGTS)autoimmuneheparin‐induced thrombocytopenia and thrombosis (HITT)platelet factor 4 (PF4)vaccine‐induced immune thrombocytopenia and thrombosis (VITT)

Substanzen

Platelet Factor 4HeparinAutoantibodiesImmunoglobulin G

Autor:innen und Institutionen

  • Department of Pathology and Molecular Medicine, McMaster University, Ontario, Canada.
  • Department of Medicine, McMaster University, Ontario, Canada.

ORCID-Profile: Theodore E Warkentin

Zitieren

APA

Warkentin, T. E. (2026). Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders. International Journal of Laboratory Hematology, 48(2), 259-271. https://doi.org/10.1111/ijlh.14486

Vancouver

Warkentin TE. Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders. International Journal of Laboratory Hematology. 2026;48(2):259-271. doi:10.1111/ijlh.14486

BibTeX
@article{Warkentin2026,
  author = {Warkentin, Theodore E},
  title = {Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders},
  journal = {International Journal of Laboratory Hematology},
  year = {2026},
  volume = {48},
  number = {2},
  pages = {259--271},
  doi = {10.1111/ijlh.14486}
}
Kostenlos starten →